Back to Search Start Over

Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3.

Authors :
Kemény, Lajos
Berggren, Lovisa
Dossenbach, Martin
Dutronc, Yves
Paul, Carle
Source :
Journal of Dermatological Treatment. Feb2019, Vol. 30 Issue 1, p19-26. 8p.
Publication Year :
2019

Abstract

Purpose: To evaluate short- and long-term efficacy and safety of ixekizumab in patients according to psoriasis severity. Materials and methods: Data were integrated from clinical trials (UNCOVER-2, UNCOVER-3). Patients received placebo, 80-mg ixekizumab every 2 weeks (IXEQ2W), every 4 weeks (IXEQ4W), or 50 mg etanercept (ETN) biweekly for 12 weeks, then open-label IXEQ4W (UNCOVER-3). Psoriasis severity was categorized by baseline Psoriasis Area and Severity Index (PASI <20 and ≥20). Efficacy was evaluated by percentage reaching PASI 75, 90, 100, and absolute PASI ≤5, ≤2, and ≤1. Results: Significantly more patients with PASI ≥20 (vs. PASI <20) were male and had higher body weight. After 12 weeks, both severity groups had significantly more IXEQ2W- than ETN-treated patients reach PASI 75, 90, 100, and absolute PASI ≤5, ≤2, ≤1. Fewer PASI ≥20 vs. PASI <20 patients across treatments reached PASI ≤5, ≤2, and ≤1 at week 12. Efficacy was maintained during 156 weeks of ixekizumab treatment with no differences between groups. The IXEQ2W safety profile was similar between groups except for injection-site reactions (significantly higher in PASI <20). Conclusions: Ixekizumab demonstrated a high level of efficacy and had a consistent safety profile in patients with different baseline psoriasis severity levels. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
*PSORIASIS
*PATIENT safety

Details

Language :
English
ISSN :
09546634
Volume :
30
Issue :
1
Database :
Academic Search Index
Journal :
Journal of Dermatological Treatment
Publication Type :
Academic Journal
Accession number :
135500933
Full Text :
https://doi.org/10.1080/09546634.2018.1473551